(Last)

(First)

(Middle)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL				
OMB Number:	3235-0287			
Estimated average burden				
hours per response:	0.5			

CHANGES IN BENEFICIAL OWNERSHIP

Check this box Section 16. For may continue.	m 4 or Form 5 of	obligations	SIA		Filed p	ursuar	nt to Secti	on 16(a)	of the Se	curitie	es Exchang	e Act	of 1934	:RSHIP	
Name and Address of Reporting Person* Manko Joseph M. Jr.				or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol KORU Medical Systems, Inc. [KRMD]							(Chec	5. Relationsh (Check all ap			
(Last) (First) (Middle) 1717 ARCH STREET 39TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 09/30/2022								Ot be			
(Street) PHILADELPHIA PA 19103				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indi	Fo			
(City)	(State)	(Zi	ip)												
		Т	able I - No	_					_	Disp	1				_
1. Title of Security (Instr. 3)			Date	ansacti nth/Day		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4				5. A Sec Ben Foll- Trar	
									Code	v	Amount		(A) or (D)	Price	3 an
Common Stock			09	9/30/2022		A		6,68	6,681		\$0 ⁽¹⁾				
Common Stock															
			Table II -								sed of, onvertible				ed
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Da		ate, Transac		5. Num Deriva Securi Acquir or Disp	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour Securities Underly Derivative Security (Instr. 3 and 4)		nount of derlying curity	8. Pr Deriv Secu (Inst
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	,	Amount or Number of Shares	
1. Name and Add	•	ting Person*													
(Last) 1717 ARCH S 39TH FLOOR		st)	(Middle)												
(Street) PHILADELPH	HIA PA		19103												
(City)	(Sta	ate)	(Zip)												
1. Name and Addi <u>Horton Cap</u>		ing Person* g <u>ement, LLC</u>													
(Last) 1717 ARCH S 39TH FLOOR		st)	(Middle)												
(Street) PHILADELPH	HIA PA		19103												
(City)	(Sta	ate)	(Zip)												
1. Name and Add <u>Horton Cap</u>		-													

OMB APPROVAL				
OMB Number:	3235-0287			
Estimated average burden				
hours per response:	0.5			

10% Owner

below)

6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

Other (specify

7. Nature of

Indirect Beneficial Ownership (Instr. 4)

By Horton Capital

Partners

Freedom, L.P.(2)

11. Nature of Indirect Beneficial

Ownership

(Instr. 4)

Fund, $LP^{(2)}$ By Horton

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person

Director

below)

5. Amount of

5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)

7,426,330

3,067,369

9. Number of derivative

Securities

Beneficially

Beneficially Owned Following Reported Transaction(s) (Instr. 4)

8. Price of Derivative

Security (Instr. 5)

Officer (give title

1717 ARCH STREE 39TH FLOOR	ET		
(Street)			
PHILADELPHIA	PA	19103	
(City)	(State)	(Zip)	
1. Name and Address of Horton Capital F	. •	. <u>P.</u>	
(Last)	(First)	(Middle)	
1717 ARCH STREE	ET		
39TH FLOOR			
(Street)			
PHILADELPHIA	PA	19103	
(City)	(State)	(Zip)	
1. Name and Address of Horton Freedom			
(Last)	(First)	(Middle)	
1717 ARCH STREE	T		
39TH FLOOR			
(Street)			
PHILADELPHIA	PA	19103	
(City)	(State)	(Zip)	

Explanation of Responses:

- 1. See Exhibit 99.1 to this Form 4 for explanation of note (1).
- 2. See Exhibit 99.1 to this Form 4 for explanation of note (2).

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person.

/s/ Joseph M. Manko, Jr.	10/03/2022
/s/ Joseph M. Manko, Jr.,	
Managing Member of Horton	10/03/2022
Capital Management, LLC	
/s/ Joseph M. Manko, Jr.,	
Managing Member of Horton	10/03/2022
Capital Partners, LLC	
/s/ Joseph M. Manko, Jr.,	
Managing Member of Horton	
Capital Partners, LLC, the General	10/03/2022
Partner of Horton Capital Partners	
Fund, LP	
/s/ Joseph M. Manko, Jr.,	
Managing Member of Horton	10/03/2022
Capital Partners, LLC, the General	10/03/2022
Partner of Horton Freedom, L.P.	
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

EXHIBIT 99.1 TO FORM 4

Explanation of Responses:

- (1) On September 30, 2022, Horton Capital Partners Fund, LP, a Delaware limited partnership ("HCPF"), was granted 6,681 shares of Repro Med Systems, Inc. (the "Issuer") common stock ("Common Stock") in consideration for Mr. Manko's service as a Director of the Issuer for the quarter ended September 30, 2022.
- (2) This Form 4 is filed jointly by Horton Capital Management, LLC, a Delaware limited liability company ("HCM"), Horton Capital Partners LLC, a Delaware limited liability company ("HCP"), HCPF, and Joseph M. Manko, Jr. Pursuant to investment advisory agreements, HCM maintains investment and voting power with respect to shares of Common Stock of the Issuer held by HCPF and Horton Freedom, L.P., a Delaware limited partnership ("Horton Freedom"). However, despite the delegation of investment and voting power to HCM, HCP may be deemed to be the beneficial owner of such Common Stock because, in the event HCM's investment advisory agreement with respect to such Common Stock is terminated, HCP has the right to assume HCM's discretionary investment and voting authority with respect to such Common Stock. HCP is the general partner of HCPF and Horton Freedom. Mr. Manko is the managing member of both HCM and HCP.

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person.